2021-06-10T00:00:00.000+10:00
Ongoing

CPOST

CPOST
Skin cancer

A randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.

A randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.

Trial overview

Topic

Skin cancer

Trial registration

Number: NCT03969004

Study details

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).

Further information

For further information regarding this clinical trial click here.

Location

GenesisCare Bundaberg (Oncology) – PI: Gerry Adams

GenesisCare Bundaberg (Oncology) – PI: Gerry Adams :::

GenesisCare Tugun (Oncology) – PI: Sid Baxi

GenesisCare Tugun (Oncology) – PI: Sid Baxi :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.